Summary
This 8-K filing from IDEXX LABORATORIES INC /DE (IDXX) reports on significant leadership changes and executive compensation adjustments. Following a serious injury to CEO Jonathan W. Ayers, Jay Mazelsky has been appointed Interim President and Chief Executive Officer. Mr. Mazelsky will continue to manage key aspects of the Companion Animal Group Commercial Organization and innovation portfolio, including global in-house diagnostics and Veterinary Software and Services. In recognition of their expanded roles, both Mr. Mazelsky and CFO Brian McKeon have been granted special equity awards. Mr. Mazelsky received awards valued at approximately $2 million, comprising stock options and restricted stock units, while Mr. McKeon received awards valued at approximately $1 million. These awards vest over five years and are intended to recognize their increased responsibilities during this period.
Key Highlights
- 1Jay Mazelsky appointed Interim President and CEO due to a serious injury to Jonathan W. Ayers.
- 2Mr. Mazelsky will continue to oversee North American Companion Animal Group Commercial Organization and key innovation areas.
- 3CFO Brian McKeon assumes additional oversight for Water, Livestock, Poultry, and Dairy business segments, as well as LATAM Companion Animal Group and OPTI Medical Systems.
- 4Jay Mazelsky receives a special equity award valued at approximately $2 million (stock options and RSUs).
- 5Brian McKeon receives a special equity award valued at approximately $1 million (stock options and RSUs).
- 6Both equity awards vest ratably over five years, contingent on continued employment.
- 7Awards granted under the Company's 2018 Stock Incentive Plan.